Neurodegenerative diseases are progressive disorders that affect the central nervous system (CNS) and represent the major cause of premature death in the elderly. One of the possible determinants of neurodegeneration is the change in mitochondrial function and content. Altered levels of mitochondrial DNA copy number (mtDNA-CN) in biological fluids have been reported during both the early stages and progression of the diseases. In patients affected by neurodegenerative diseases, changes in mtDNA-CN levels appear to correlate with mitochondrial dysfunction, cognitive decline, disease progression, and ultimately therapeutic interventions. In this review, we report the main results published up to April 2024, regarding the evaluation of mtDNA-CN levels in blood samples from patients affected by Alzheimer’s (AD), Parkinson’s (PD), and Huntington’s diseases (HD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). The aim is to show a probable link between mtDNA-CN changes and neurodegenerative disorders. Understanding the causes underlying this association could provide useful information on the molecular mechanisms involved in neurodegeneration and offer the development of new diagnostic approaches and therapeutic interventions.
Background: Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition frequently accompanied by behavioral dysregulation. While genetic factors involving monoaminergic systems have been implicated, emerging evidence suggests a role for mitochondrial dysfunction in ADHD pathophysiology. Mitochondrial DNA copy number (mtDNA-cn), a surrogate marker of mitochondrial biogenesis and cellular energy demand, may reflect underlying neurobiological alterations and oxidative stress-related mechanisms relevant to ADHD. Methods: We assessed mtDNA-cn in the peripheral blood of 56 Italian children and adolescents with ADHD and 27 age- and sex-matched healthy controls. ADHD symptoms and aggressive behavior were evaluated using DSM-5 criteria and the Conners’ 3 Rating Scales. Genotyping was performed for MAOA (rs6323, rs1137070) and 5-HTT (rs4795541) polymorphisms. Results: ADHD patients showed significantly higher mtDNA-cn than controls (p = 0.002), supporting mitochondrial dysregulation. Comparing the ADHD patient subgroups with aggressive behavior and those without, a non-significant reduction in mtDNA-cn was observed in the first subgroup. Notably, individuals with the TT genotype (rs6323) or CC genotype (rs1137070) had significantly higher mtDNA-cn compared to controls with the same genotypes (p = 0.031). Similar increases were seen across all 5-HTT rs4795541 genotypes in ADHD patients. Conclusions: Our findings suggest that mitochondrial alterations may contribute to ADHD pathophysiology. The association between mtDNA-cn and monoaminergic gene variants highlights a potential link between neurotransmitter metabolism, oxidative stress, and mitochondrial function. Thus, mtDNA-cn may serve as a peripheral biomarker and therapeutic target in ADHD.
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder with marked clinical heterogeneity and increased tumor risk, complicating disease surveillance, risk stratification and treatment decisions. This review summarizes current evidence on transcriptomic approaches relevant to NF1, with particular emphasis on extracellular vesicles (EVs), EV-associated RNA and bioinformatic strategies. NF1-specific evidence on EVs remains limited and has mainly addressed EV-associated proteins, biological effects and experimental models, whereas comprehensive transcriptomic profiling of circulating EVs in well-characterized NF1 cohorts remains largely unexplored. Transcriptomic and multi-omics studies of NF1-associated tumors provide complementary information on molecular heterogeneity, tumor progression and the tumor microenvironment, while studies of EV-associated RNA in other diseases provide a broader biological and methodological framework. Bioinformatic approaches may facilitate the processing and integration of EV-associated RNA datasets, the identification of candidate molecular signatures and their integration with clinical and genomic information. However, the diagnostic, prognostic and predictive value of EV-associated RNAs in NF1 remains investigational and requires independent clinical validation. Future studies should focus on well-characterized longitudinal cohorts, standardized EV isolation and characterization, reproducible analytical workflows and integration of molecular profiles with clinical and genomic data. These approaches may determine whether EV-associated transcriptomic signatures can contribute to disease characterization, risk stratification and treatment monitoring in NF1.
Cardiovascular diseases (CVDs) remain a leading cause of death worldwide. Mitochondria, essential organelles within cells, play a crucial role in maintaining cardiovascular health by producing energy through ATP synthesis. The heart’s high energy demand makes it particularly sensitive to mitochondrial function. In CVDs, mitochondrial adaptability is compromised, resulting in dysfunction characterized by impaired respiratory chain activity, decreased ATP production, oxidative stress, and structural damage. This review consolidates current research on mitochondrial roles in CVD development, focusing on mitochondrial respiration, ATP synthesis, and the processes involved in maintaining mitochondrial quality, such as mitophagy. It discusses the challenges in developing therapies aimed at restoring mitochondrial function, including drug delivery issues and targeting specificity. The assessment includes analysis of mitochondrial anomalies associated with cardiac disease progression and potential therapeutic strategies. Mitochondrial dysfunction contributes to the progression of various CVDs by reducing energy output and increasing oxidative stress, leading to cardiomyocyte injury and death. Damaged mitochondria produce excessive reactive oxygen species (ROS), exacerbating cellular damage. Repairing mitochondrial components, especially the respiratory chain and ATP synthesis pathways, has shown potential in mitigating cellular injury and improving cardiac function. Restoring mitochondrial function is vital for preventing and treating CVDs. Targeted therapies that repair mitochondrial respiratory activity and enhance ATP production may reduce cellular damage, promote cardiomyocyte survival, and improve clinical outcomes. Understanding mitochondrial dynamics offers promising avenues for innovative interventions in cardiovascular health management.
Pathogenic variants localized in the gene coding for the Fukutin-Related Protein (FKRP) are responsible for Limb-Girdle Muscular Dystrophy type 9 (LGMDR9), Congenital Muscular Dystrophies type 1C (MDC1C), Walker–Warburg Syndrome (WWS), and Muscle–Eye–Brain diseases (MEBs). LGMDR9 is the fourth most common hereditary Limb Girdle Muscular Dystrophy in Italy. LGMDR9 patients with severe disease show an overlapping Duchenne/Becker phenotype and may have secondary dystrophin reduction on muscle biopsy. We conducted a molecular analysis of the FKRP gene by direct sequencing in 153 patients from Southern Italy (Calabria) with Duchenne/Becker-like phenotypes without confirmed genetic diagnosis. Mutational screening of the patients (112 men and 41 women, aged between 5 and 84 years), revealed pathogenic variants in 16 subjects. The most frequent variants identified were c.427C > A, p.R143S, and c.826C > A, p.L276I (NM_024301.5). The results obtained show that the Duchenne/Becker-like phenotype is frequently determined by mutations in the FKRP gene in our cohort and highlight the importance of considering LGMDR9 in the differential diagnosis of dystrophinopathies in Calabria. Finally, this study, which, to our knowledge, is the first conducted on Calabrian subjects, will contribute to the rapid identification and management of LGMDR9 patients.